Clinical Trial Results

Showing: All studies [change]
Condition: Cancer Location: Pennsylvania 25 trials found
New Search
Filter
Trial Phase
Study Type
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
PHASE3INTERVENTIONAL Anchorage, Alaska +4 more
RECRUITING
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
PHASE3INTERVENTIONAL Birmingham, Alabama +4 more
RECRUITING
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
PHASE3INTERVENTIONAL Birmingham, Alabama +4 more
RECRUITING
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
PHASE2, PHASE3INTERVENTIONAL Birmingham, Alabama +4 more
RECRUITING
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
PHASE3INTERVENTIONAL Birmingham, Alabama +4 more
RECRUITING
Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability
PHASE3INTERVENTIONAL Phoenix, Arizona +4 more
RECRUITING
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
N/AOBSERVATIONAL Fairbanks, Alaska +4 more
RECRUITING
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
PHASE2INTERVENTIONAL Gilbert, Arizona +4 more
RECRUITING
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
PHASE2INTERVENTIONAL Daphne, Alabama +4 more
RECRUITING
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
PHASE3INTERVENTIONAL Phoenix, Arizona +4 more
RECRUITING
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
PHASE2INTERVENTIONAL Jonesboro, Arkansas +4 more
RECRUITING
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
PHASE3INTERVENTIONAL Gilbert, Arizona +4 more
RECRUITING
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
PHASE2, PHASE3INTERVENTIONAL Daphne, Alabama +4 more
RECRUITING
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
PHASE3INTERVENTIONAL Mobile, Alabama +4 more
RECRUITING
Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers
PHASE2INTERVENTIONAL Birmingham, Alabama +4 more
RECRUITING
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
PHASE3INTERVENTIONAL Anchorage, Alaska +4 more
RECRUITING
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
PHASE2INTERVENTIONAL Birmingham, Alabama +4 more
RECRUITING
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
PHASE3INTERVENTIONAL Tucson, Arizona +4 more
RECRUITING
Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
PHASE2, PHASE3INTERVENTIONAL Birmingham, Alabama +4 more
RECRUITING
Tempus Small Cell Lung Cancer Observational Study (Sculptor)
N/AOBSERVATIONAL Los Alamitos, California +4 more
RECRUITING
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
PHASE1, PHASE2INTERVENTIONAL Santa Rosa, California +4 more
RECRUITING
GEMINI-NSCLC: NSCLC Biomarker Study
N/AOBSERVATIONAL Birmingham, Alabama +4 more
RECRUITING
Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays
N/AOBSERVATIONAL Fort Smith, Arkansas +4 more
RECRUITING
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
PHASE3INTERVENTIONAL Dothan, Alabama +4 more
RECRUITING
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
PHASE3INTERVENTIONAL Daphne, Alabama +4 more
RECRUITING
Filter Trials
Trial Phase
Study Type